3/10/2023 0 Comments Netspot aaa![]() ![]() “New Jersey was our first choice of location for our U.S. The site is conveniently located near Newark airport, enabling future delivery of lutetium Lu 177 dotatate (Lutathera®)* directly to hospitals and treatment centers around the country. ![]() The facility is undergoing validation to produce AAA’s investigational therapy, lutetium Lu 177 dotatate (Lutathera®)*, and currently serves as a distribution center for its NETSPOT® diagnostic drug and Oxygen-18 enriched water, an important precursor for the production of fluorodeoxyglucose (FDG) used in PET. In 2016, AAA officially opened its first production and distribution site in Milburn, New Jersey. office in New York City in 2014, and listed on the NASDAQ in 2015. In line with AAA’s growth strategy, the company has built a substantial beachhead in the United States. The team’s research produced a patent, which had applications in nuclear medicine, and Buono saw an opportunity to create a company to commercialize this patent and further develop the technology for theragnostic applications. Prior to founding AAA, Stefano Buono was a physicist at The European Organization for Nuclear Research (CERN) in Switzerland, working with Physics Nobel Laureate Carlo Rubbia. AAA is also developing a pipeline of theragnostic pairings for oncology indications. AAA employs over 500 employees in 13 countries (Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the U.S.) and currently markets nine radiopharmaceuticals (8 in Europe and 1 in the U.S.) for diagnosis in oncology, cardiology and neurology. that manufacture both diagnostic and therapeutic MNM products. Today, AAA has over 21 production and research & development facilities in Europe and the U.S. ![]() AAA, headquartered in Saint-Genis-Pouilly, France was founded in 2002 by Stefano Buono. AAA is merging therapeutic and diagnostic technologies to advance the early detection, treatment and monitoring of diseases. ![]() AAA is a global leader in the development of predictive, preventive and personalized tools that may transform healthcare for patients and physicians. We celebrate you! Admera Health is one such company.Īdvanced Accelerator Applications (AAA) is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, diagnostic and therapeutic products. ITM had a generator for a long time under development that could compensate shortages for at least the next two years, but it still is not approved.” To conserve generator lifespan, distributors have resorted to self-imposed blackouts for NETSPOT doses, creating insufficient supplies and delays in procedures.So many of our Members are making a dramatic impact on our State’s innovation ecosystem. IRE has now a generator with MA but due to internal reorganization, has not yet started growing capacity. “E&Z needs to build a new facility that itself needs approval from authorities, hence the date of mid-2019 to be ready. “The three companies able to sell generators or with generators under development underestimated the volume,” Richard Zimmermann, co-founder and partner of MEDraysintell and founder and senior consultant of nuclear medicine at Chrysalium Consulting SARL, told HCB News. Though planning to expand production with the construction of a new facility, E&Z will not be able to commence manufacturing there until mid-2019. Such needs have exacerbated production of Ge-68/Ga-68 generators, leading to waiting periods of between 14 and 18 months. The AAA reports that many often hit their elution limit before the end of one year. The solution is approved for 400 elutions or for use of up to one year, adding to demand with requests for replacements when such marks are reached. Since its 2016 approval under E&Z, demand for the somatostatin receptor PET tracer has increased among those treating neuroendocrine tumors (NETs) in adult and pediatric patients, quickly replacing its market predecessor due to its patient-friendly regimen as an injection, reduction of imaging exams to approximately three hours, and its coverage by payors. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |